VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | OPB-11077 for newly diagnosed and R/R AML: Phase Ib update

Lindsay Wilde, MD, Thomas Jefferson University, Philadelphia, PA, discusses the results of the Phase Ib dose-escalating study (NCT03063944) evaluating the safety and efficacy of OPB-111077, a novel mitochondrial electron transport inhibitor, in addition to a venetoclax plus decitabine regimen in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML). Although the efficacy number are small, two out of nine patients achieved complete remission, where three patients died due to disease progression. OPB-111077 was generally well tolerated, with no dose-limiting toxicity observed. The most common adverse effects (AE) grade ≥3 were febrile neutropenia in 56% of patients, and muscle weakness in 11% of patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter